Patents by Inventor Dhruva Katrekar

Dhruva Katrekar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA targeting of mutations via suppressor tRNAs and deaminases
    Patent number: 11932856
    Abstract: Aspects of the disclosure relate to a gene therapy approach for diseases, disorders, or conditions caused by mutation in the stop codon utilizing modified tRNA. At least 10-15% of all genetic diseases, including muscular dystrophy (e.g. Duchene muscular dystrophy), some cancers, beta thalassemia, Hurler syndrome, and cystic fibrosis, fall into this category. Not to be bound by theory, it is believed that this approach is safer than CRISPR approaches due to minimal off-target effects and the lack of genome level changes.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: March 19, 2024
    Assignee: The Regents of the University of California
    Inventors: Prashant Mali, Dhruva Katrekar
  • RNA AND DNA BASE EDITING VIA ENGINEERED ADAR
    Publication number: 20230313231
    Abstract: Disclosed herein are engineered ADAR systems for gene editing.
    Type: Application
    Filed: September 8, 2021
    Publication date: October 5, 2023
    Inventors: Prashant Mali, Dhruva Katrekar, Nathan Palmer
  • RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES
    Publication number: 20230139474
    Abstract: Aspects of the disclosure relate to a gene therapy approach for diseases, disorders, or conditions caused by mutation in the stop codon utilizing modified tRNA. At least 10-15% of all genetic diseases, including muscular dystrophy (e.g. Duchene muscular dystrophy), some cancers, beta thalassemia, Hurler syndrome, and cystic fibrosis, fall into this category. Not to be bound by theory, it is believed that this approach is safer than CRISPR approaches due to minimal off-target effects and the lack of genome level changes.
    Type: Application
    Filed: August 25, 2022
    Publication date: May 4, 2023
    Inventors: Prashant Mali, Dhruva Katrekar
  • RNA targeting of mutations via suppressor tRNAs and deaminases
    Patent number: 11608503
    Abstract: Aspects of the disclosure relate to a gene therapy approach for diseases, disorders, or conditions caused by mutation in the stop codon utilizing modified tRNA. At least 10-15% of all genetic diseases, including muscular dystrophy (e.g. Duchene muscular dystrophy), some cancers, beta thalassemia, Hurler syndrome, and cystic fibrosis, fall into this category. Not to be bound by theory, it is believed that this approach is safer than CRISPR approaches due to minimal off-target effects and the lack of genome level changes.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: March 21, 2023
    Assignee: The Regents of the University of California
    Inventors: Prashant Mali, Dhruva Katrekar
  • TARGETING TRANSFER RNA FOR THE SUPPRESSION OF NONSENSE MUTATIONS IN MESSENGER RNA
    Publication number: 20230053353
    Abstract: The disclosure provides for a targeting transfer RNA (ttRNA) that that suppresses nonsense mutations in messenger RNA, that comprises an anticodon sequence that binds to a stop codon and a variable loop sequence that comprises an RNA aptamer that has strong binding affinity to an RNA binding protein; and methods of use thereof.
    Type: Application
    Filed: January 8, 2021
    Publication date: February 23, 2023
    Inventors: Prashant Mali, Dhruva Katrekar, Thomas Morton
  • ENGINEERING CIRCULAR GUIDE RNAS
    Publication number: 20230036370
    Abstract: Disclosed herein are engineered guide RNAs, constructs for forming engineered guide RNAs, pharmaceutical compositions thereof, methods of making the engineered guide RNAs, and methods of treating or preventing a diseases and disorders of a subject by administering one or more of the engineered guide RNAs or the constructs for forming the engineered guide RNAs.
    Type: Application
    Filed: December 1, 2020
    Publication date: February 2, 2023
    Inventors: Prashant Mali, Dhruva Katrekar
  • RNA targeting of mutations via suppressor tRNAs and deaminases
    Patent number: 11479775
    Abstract: Aspects of the disclosure relate to a gene therapy approach for diseases, disorders, or conditions caused by mutation in the stop codon utilizing modified tRNA. At least 10-15% of all genetic diseases, including muscular dystrophy (e.g. Duchene muscular dystrophy), some cancers, beta thalassemia, Hurler syndrome, and cystic fibrosis, fall into this category. Not to be bound by theory, it is believed that this approach is safer than CRISPR approaches due to minimal off-target effects and the lack of genome level changes.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: October 25, 2022
    Assignee: The Regents of the University of California
    Inventors: Prashant Mali, Dhruva Katrekar
  • RNA TARGETING OF MUTATIONS VIA SUPPESSOR tRNAs AND DEAMINASES
    Publication number: 20220186226
    Abstract: Aspects of the disclosure relate to a gene therapy approach for diseases, disorders, or conditions caused by mutation in the stop codon utilizing modified tRNA. At least 10-15% of all genetic diseases, including muscular dystrophy (e.g. Duchene muscular dystrophy), some cancers, beta thalassemia, Hurler syndrome, and cystic fibrosis, fall into this category. Not to be bound by theory, it is believed that this approach is safer than CRISPR approaches due to minimal off-target effects and the lack of genome level changes.
    Type: Application
    Filed: March 4, 2022
    Publication date: June 16, 2022
    Inventors: Prashant Mali, Dhruva Katrekar
  • RNA AND DNA BASE EDITING VIA ENGINEERED ADAR RECRUITMENT
    Publication number: 20220010333
    Abstract: Disclosed herein is a system to recruit ADARs to catalyze therapeutic editing of point mutations via the use of engineered RNA scaffolds, engineered DNA scaffolds or DNA-RNA hybrid scaffolds. The system comprises an engineered ADAR2 guide RNA (adRNA) that bears a 20-100 bp complementarity with the target RNA and ADAR2 recruiting domain from the GluR2 mRNA at either or both the 5? end or the 3? end.
    Type: Application
    Filed: September 6, 2019
    Publication date: January 13, 2022
    Inventors: Prashant Mali, Dhruva Katrekar, Dario Meluzzi, Genghao Chen, Kyle M. Ford
  • RNA TARGETING OF MUTATIONS VIA SUPPESSOR tRNAs AND DEAMINASES
    Publication number: 20210198673
    Abstract: Aspects of the disclosure relate to a gene therapy approach for diseases, disorders, or conditions caused by mutation in the stop codon utilizing modified tRNA. At least 10-15% of all genetic diseases, including muscular dystrophy (e.g. Duchene muscular dystrophy), some cancers, beta thalassemia, Hurler syndrome, and cystic fibrosis, fall into this category. Not to be bound by theory, it is believed that this approach is safer than CRISPR approaches due to minimal off-target effects and the lack of genome level changes.
    Type: Application
    Filed: February 8, 2021
    Publication date: July 1, 2021
    Inventors: Prashant Mali, Dhruva Katrekar
  • RNA TARGETING OF MUTATIONS VIA SUPPESSOR tRNAs AND DEAMINASES
    Publication number: 20210163948
    Abstract: Aspects of the disclosure relate to a gene therapy approach for diseases, disorders, or conditions caused by mutation in the stop codon utilizing modified tRNA. At least 10-15% of all genetic diseases, including muscular dystrophy (e.g. Duchene muscular dystrophy), some cancers, beta thalassemia, Hurler syndrome, and cystic fibrosis, fall into this category. Not to be bound by theory, it is believed that this approach is safer than CRISPR approaches due to minimal off-target effects and the lack of genome level changes.
    Type: Application
    Filed: February 8, 2021
    Publication date: June 3, 2021
    Inventors: Prashant Mali, Dhruva Katrekar
  • CRISPR-CAS GENOME ENGINEERING VIA A MODULAR AAV DELIVERY SYSTEM
    Publication number: 20200340012
    Abstract: The present disclosure relates to a novel delivery system with unique modular CRISPR-Cas9 architecture that allows better delivery, specificity and selectivity of gene editing. It represents significant improvement over previously described split-Cas9 systems. The modular architecture is “regulatable”. Additional aspects relate to systems that can be both spatially and temporally controlled, resulting in the potential for inducible editing. Further aspects relate to a modified viral capsid allowing conjugation to homing agents.
    Type: Application
    Filed: August 18, 2017
    Publication date: October 29, 2020
    Inventors: Prashant Mali, Dhruva Katrekar, Ana Moreno Collado
  • RNA TARGETING OF MUTATIONS VIA SUPPESSOR tRNAs AND DEAMINASES
    Publication number: 20200277607
    Abstract: Aspects of the disclosure relate to a gene therapy approach for diseases, disorders, or conditions caused by mutation in the stop codon utilizing modified tRNA. At least 10-15% of all genetic diseases, including muscular dystrophy (e.g. Duchene muscular dystrophy), some cancers, beta thalassemia, Hurler syndrome, and cystic fibrosis, fall into this category. Not to be bound by theory, it is believed that this approach is safer than CRISPR approaches due to minimal off-target effects and the lack of genome level changes.
    Type: Application
    Filed: May 1, 2020
    Publication date: September 3, 2020
    Applicant: The Regents of the University of California
    Inventors: Prashant Mali, Dhruva Katrekar
  • RNA TARGETING OF MUTATIONS VIA SUPPESSOR tRNAs AND DEAMINASES
    Publication number: 20200263180
    Abstract: Aspects of the disclosure relate to a gene therapy approach for diseases, disorders, or conditions caused by mutation in the stop codon utilizing modified tRNA. At least 10-15% of all genetic diseases, including muscular dystrophy (e.g. Duchene muscular dystrophy), some cancers, beta thalassemia, Hurler syndrome, and cystic fibrosis, fall into this category. Not to be bound by theory, it is believed that this approach is safer than CRISPR approaches due to minimal off-target effects and the lack of genome level changes.
    Type: Application
    Filed: March 2, 2018
    Publication date: August 20, 2020
    Inventors: Prashant Mali, Dhruva Katrekar